Patents by Inventor Travis Wilson

Travis Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200376072
    Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Applicant: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Publication number: 20200360462
    Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or severity of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and/or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and/or cardiac troponin I, and/or reduce expression levels of MLCL AT1 and/or ALCAT 1 in subjects in need thereof.
    Type: Application
    Filed: December 20, 2019
    Publication date: November 19, 2020
    Applicants: Stealth Bio Therapeutics Corp, Henry Ford Health Systems
    Inventors: D. Travis Wilson, Hani N. Sabbah
  • Patent number: 10835573
    Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: November 17, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Publication number: 20200345803
    Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
    Type: Application
    Filed: July 15, 2020
    Publication date: November 5, 2020
    Applicant: Stealth BioTherapeutics Corp
    Inventors: D. Travis Wilson, Mark Bamberger
  • Publication number: 20200323947
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: January 17, 2020
    Publication date: October 15, 2020
    Applicant: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Publication number: 20200316160
    Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.
    Type: Application
    Filed: December 2, 2019
    Publication date: October 8, 2020
    Applicant: Stealth Bio Therapeutics Corp
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Patent number: 10793597
    Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: October 6, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Publication number: 20200308221
    Abstract: The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: March 9, 2020
    Publication date: October 1, 2020
    Applicant: STEALTH BIOTHERAPEUTICS CORP
    Inventors: Scott DUNCAN, D. Travis WILSON
  • Patent number: 10744178
    Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: August 18, 2020
    Assignee: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Patent number: 10749989
    Abstract: The present disclosure describes an exemplary hybrid client/server architecture that may be utilized leverage the unique capabilities of both remote and local services. Data may be processed in parallel by remote and local processes. Results generated during the parallel processing may be exchanged between remote and local services and used to update results generated by the separate services. The hybrid client/server architecture may be utilized to generate enhanced inferences, hybrid subscriptions base upon local and remote subscriptions, and enhance natural language expression evaluation services.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: August 18, 2020
    Assignee: Microsoft Technology Licensing LLC
    Inventors: Christopher Dac Le, Michael Calcagno, Jon Hamaker, Rob Chambers, Michael Plumpe, Travis Wilson
  • Publication number: 20200223887
    Abstract: The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 16, 2020
    Applicants: Stealth Biotherapeutics Corp, Mayo Foundation for Medical Education and Research
    Inventors: D. Travis Wilson, Lilach O. Lerman, Stephen C. Textor
  • Patent number: 10702577
    Abstract: The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: July 7, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 10696716
    Abstract: The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: June 30, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Publication number: 20200165110
    Abstract: A utility vehicle having a collapsible game hanger apparatus includes a cargo box, a hitch receiver disposed under the cargo box and included in a rear structure, a hoist structure, a winch device, and a winch mounting bracket. The hoist structure consists of a base bar detachably attached to the hitch receiver, a mast attached to an end portion of the base bar, and a boom attached to an upper end of the mast. The winch device consists essentially of a winch detachably attached to a winch mounting bracket and a pulley unit for guiding the winch cable.
    Type: Application
    Filed: November 27, 2018
    Publication date: May 28, 2020
    Applicant: KUBOTA CORPORATION
    Inventors: Travis WILSON, Aubrey JARVIS
  • Patent number: 10646539
    Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: May 12, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 10633415
    Abstract: The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: April 28, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventors: Scott Duncan, D. Travis Wilson
  • Patent number: 10627392
    Abstract: The present technology provides methods for detecting and diagnosing diseases and conditions characterized by mitochondrial dysfunction using monocytes as an indicator of the dysfunction.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: April 21, 2020
    Assignee: Stealth Biotherapeutics Corp
    Inventor: D. Travis Wilson
  • Publication number: 20200113966
    Abstract: The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction.
    Type: Application
    Filed: June 11, 2019
    Publication date: April 16, 2020
    Applicant: Stealth BioTherapeutics Corp.
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Patent number: 10576124
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: March 3, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Publication number: 20200024308
    Abstract: The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: February 28, 2019
    Publication date: January 23, 2020
    Applicant: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson